Ad-LIF-IL-24共表达腺病毒载体对胶质瘤细胞的抑癌增效和分子机制的研究
|
摘要
目的:构建LIF和IL-24双基因共表达腺病毒载体(Ad-LIF-IL-24),研究其对胶质瘤细胞的抑癌增效和分子机制。
方法:分别以pORF-mbcl-2α质粒为模板,PCR分别扩增出polyA和promoter基因片段,再以此为模板,经SOE-PCR扩增polyA+promoter(SalI、NotI)融合片段,并突变其中的PacⅠ酶切位点。再以pcDNA3.0-LIF质粒和pAdTrack-CMV-IL-24质粒为模板,PCR扩增出LIF(BglII、SalI)和IL-24(XhoI、XbaI)目的片段,并与突变后polyA+promoter(简称polyA+promoter△)依次亚克隆至pAdTrack-CMV转移质粒构建pAdTrack-CMV-LIF-polyA+promoter△-IL-24双基因共表达重组转移质粒。将构建正确的pAdTrack-CMV-LIF-polyA+promoter△-IL-24重组转移质粒经PmeI酶切后与pAdEasy-1腺病毒骨架质粒在BJ5183大肠杆菌中同源重组,得到的同源重组质粒pAdEasy-1-pAdTrack-CMV-LIF-polyA+promoter△-IL-24(简称为pAd-LIF- polyA+promoter△-IL-24)经PacI酶切后再用脂质体转染QBI-293A细胞,经多轮感染和扩增后获得Ad-LIF-polyA+promoter△-IL-24(简称Ad-LIF-IL-24)双基因共表达重组腺病毒载体。将Ad-LIF-IL-24体外感染肿瘤细胞SMMC-7721、U251、HT29、A549、HL-60、K562和正常细胞WI-38,筛选出Ad-LIF-IL-24最敏感肿瘤细胞和最佳感染剂量。MTT法和FCM检测Ad-LIF-IL-24对敏感肿瘤细胞的生长抑制和诱导凋亡的增效作用,Hochest染色进一步检测肿瘤细胞凋亡的核形态特征,用RT-PCR检测与细胞凋亡和肿瘤血管形成相关基因bcl-2、bax、ICE、p53和HIF-1α的转录,Western blotting检测肿瘤细胞中的细胞凋亡执行蛋白Cleaved Caspase3的表达。
结果:成功构建了双启动子介导的LIF和IL-24双基因共表达腺病毒载体Ad-LIF-IL-24。Ad-LIF-IL-24均能高效感染实体瘤细胞和正常人胚肺二倍体成纤维细胞WI-38,但对白血病细胞感染效率很低,并且对U251胶质瘤细胞抑制作用最为明显,最佳感染剂量为100MOI。腺病毒介导的LIF和IL-24双基因共表达在体外能明显抑制U251胶质瘤细胞生长和诱导凋亡,并呈现叠加效应。分子机制检测结果表明:Ad-LIF-IL-24能明显上调U251胶质瘤细胞ICE、bax、p53和下调bcl-2、HIF-1α等基因的转录,并激活Caspase3剪切成Cleaved Caspase3片段。
结论:成功构建的LIF和IL-24双基因共表达腺病毒载体Ad-LIF-IL-24体外能明显抑制U251胶质瘤细胞生长和诱导其凋亡,并呈现叠加作用。Ad-LIF-IL-24可通过上调U251细胞中ICE、bax、p53和下调bcl-2等细胞凋亡相关基因促使Caspase3激活以及下凋与肿瘤血管形成密切相关的HIF-1α基因等途径抑制U251胶质瘤细胞的生长和诱导其凋亡。
Objective: To construct a recombinant adenoviral vector co-expressing leukaemia inhibitory factor (LIF) and interleukin-24 (IL-24) and study its enhanced anti-tumor effects on glioma cells and its mechanism.
Methods: The polyA+promoter fusion fragments, LIF, and IL-24 fragments were amplified by PCR using pORF-mbcl-2a, pcDNA3.0-LIF, and pAdTrack-CMV-IL-24 plasmids as templates, respectively, and PacI enzyme site in polyA+promoter was mutated(polyA+promoter△). Then the polyA+promoter△(SalI、NotI), LIF (BglII、SalI), and IL-24 (XhoI、XbaI) fragments were subcloned into pAdTrack-CMV transfer vector to form pAdTrack-CMV-LIF-polyA+promoter△-IL-24 and identified by PCR, double endonuclease digestion, and DNA sequencing. The pAdTrack-CMV- LIF-polyA+promoter△-IL-24 transfer vector linearized with PmeI digestion and pAdEasy-1 backbone vector were further cotransfected into the bacteria BJ5183 competent cells for homologous recombination. The resultant pAdEasy- 1-pAdTrack-CMV-LIF-polyA+promoter△-IL-24(pAd-LIF-polyA+promoter△- IL-24) homologous recombinant plasmids purified from the above BJ5183 cells were transfected into the bacterial DH5αcells competent cells to abundantly amplify pAd-LIF-polyA+promoter△-IL-24 plasmids. Then they were linearized with PacI digestion and transfected into the human embryonic kidney 293 (QBI-293A) cells by Lipofectaimne2000, leading to formation of the recombinant adenoviruses Ad-LIF-polyA+promoter△-IL-24(Ad-LIF-IL-24) co-expressing LIF and IL-24. The most sensitive cell and the best MOI of Ad-LIF-IL-24 was chosen by Ad-LIF-IL-24 infecting SMMC-7721, U251, HT29, A549, HL-60, K562 and WI-38 in vitro. The effect of enhanced growth-suppressing and apoptosis-inducing by Ad-LIF-IL-24 on the tumor cells in vitro were assessed by MTT assay and FCM, and the apoptosis of the cell nucleus were detected by Hochest staining. The expression of apoptosis- and angiogenesis-related genes (bcl-2、bax、ICE、p53 and HIF-1α) and the Cleaved Caspase3 in U251 glioma cells was determined by RT-PCR and Western blotting, respectively.
Results: The adenoviral vector co-expressing LIF and IL-24, Ad-LIF- polyA+promoter△-IL-24, was successfully constructed. More than 95% of theses tumor cells (SMMC-7721, U251, HT29, and A549) and WI-38 cells were infected by Ad-LIF-IL-24 at MOI of 50, whereas HL-60 and K562 cells were hardly infected. The growth of U251 glioma cells was significantly inhibited by Ad-LIF-IL-24 at MOI of 100. Ad-LIF-IL-24- mediated LIF and IL-24 co-expression significantly inhibited U251 glioma cells growth, induced cells apoptosis, exhibiting additive effect. Ad-LIF-IL-24 significantly up-regulated the expression of ICE、bax、p53, and Cleaved Caspase-3 and down-regulated the expression of bcl-2 and HIF-1α.
Conclusion: The adenoviral vector co-expressing LIF and IL-24 (Ad-LIF-IL-24) was successfully constructed. Ad-LIF-IL-24 had significant additive effect in suppressing U251 glioma cells growth and inducing cells apoptosis in vitro. Ad-LIF-IL -24 can up-regulate the expression of ICE、bax、p53 and down-regulate Bcl-2 resulting activation of Caspase-3 and down-regulate the expression of angiogenesis-related gene HIF-1αto exhibit significantly anti-tumor effect on U251 glioma cells in vitro .
方法:分别以pORF-mbcl-2α质粒为模板,PCR分别扩增出polyA和promoter基因片段,再以此为模板,经SOE-PCR扩增polyA+promoter(SalI、NotI)融合片段,并突变其中的PacⅠ酶切位点。再以pcDNA3.0-LIF质粒和pAdTrack-CMV-IL-24质粒为模板,PCR扩增出LIF(BglII、SalI)和IL-24(XhoI、XbaI)目的片段,并与突变后polyA+promoter(简称polyA+promoter△)依次亚克隆至pAdTrack-CMV转移质粒构建pAdTrack-CMV-LIF-polyA+promoter△-IL-24双基因共表达重组转移质粒。将构建正确的pAdTrack-CMV-LIF-polyA+promoter△-IL-24重组转移质粒经PmeI酶切后与pAdEasy-1腺病毒骨架质粒在BJ5183大肠杆菌中同源重组,得到的同源重组质粒pAdEasy-1-pAdTrack-CMV-LIF-polyA+promoter△-IL-24(简称为pAd-LIF- polyA+promoter△-IL-24)经PacI酶切后再用脂质体转染QBI-293A细胞,经多轮感染和扩增后获得Ad-LIF-polyA+promoter△-IL-24(简称Ad-LIF-IL-24)双基因共表达重组腺病毒载体。将Ad-LIF-IL-24体外感染肿瘤细胞SMMC-7721、U251、HT29、A549、HL-60、K562和正常细胞WI-38,筛选出Ad-LIF-IL-24最敏感肿瘤细胞和最佳感染剂量。MTT法和FCM检测Ad-LIF-IL-24对敏感肿瘤细胞的生长抑制和诱导凋亡的增效作用,Hochest染色进一步检测肿瘤细胞凋亡的核形态特征,用RT-PCR检测与细胞凋亡和肿瘤血管形成相关基因bcl-2、bax、ICE、p53和HIF-1α的转录,Western blotting检测肿瘤细胞中的细胞凋亡执行蛋白Cleaved Caspase3的表达。
结果:成功构建了双启动子介导的LIF和IL-24双基因共表达腺病毒载体Ad-LIF-IL-24。Ad-LIF-IL-24均能高效感染实体瘤细胞和正常人胚肺二倍体成纤维细胞WI-38,但对白血病细胞感染效率很低,并且对U251胶质瘤细胞抑制作用最为明显,最佳感染剂量为100MOI。腺病毒介导的LIF和IL-24双基因共表达在体外能明显抑制U251胶质瘤细胞生长和诱导凋亡,并呈现叠加效应。分子机制检测结果表明:Ad-LIF-IL-24能明显上调U251胶质瘤细胞ICE、bax、p53和下调bcl-2、HIF-1α等基因的转录,并激活Caspase3剪切成Cleaved Caspase3片段。
结论:成功构建的LIF和IL-24双基因共表达腺病毒载体Ad-LIF-IL-24体外能明显抑制U251胶质瘤细胞生长和诱导其凋亡,并呈现叠加作用。Ad-LIF-IL-24可通过上调U251细胞中ICE、bax、p53和下调bcl-2等细胞凋亡相关基因促使Caspase3激活以及下凋与肿瘤血管形成密切相关的HIF-1α基因等途径抑制U251胶质瘤细胞的生长和诱导其凋亡。
Objective: To construct a recombinant adenoviral vector co-expressing leukaemia inhibitory factor (LIF) and interleukin-24 (IL-24) and study its enhanced anti-tumor effects on glioma cells and its mechanism.
Methods: The polyA+promoter fusion fragments, LIF, and IL-24 fragments were amplified by PCR using pORF-mbcl-2a, pcDNA3.0-LIF, and pAdTrack-CMV-IL-24 plasmids as templates, respectively, and PacI enzyme site in polyA+promoter was mutated(polyA+promoter△). Then the polyA+promoter△(SalI、NotI), LIF (BglII、SalI), and IL-24 (XhoI、XbaI) fragments were subcloned into pAdTrack-CMV transfer vector to form pAdTrack-CMV-LIF-polyA+promoter△-IL-24 and identified by PCR, double endonuclease digestion, and DNA sequencing. The pAdTrack-CMV- LIF-polyA+promoter△-IL-24 transfer vector linearized with PmeI digestion and pAdEasy-1 backbone vector were further cotransfected into the bacteria BJ5183 competent cells for homologous recombination. The resultant pAdEasy- 1-pAdTrack-CMV-LIF-polyA+promoter△-IL-24(pAd-LIF-polyA+promoter△- IL-24) homologous recombinant plasmids purified from the above BJ5183 cells were transfected into the bacterial DH5αcells competent cells to abundantly amplify pAd-LIF-polyA+promoter△-IL-24 plasmids. Then they were linearized with PacI digestion and transfected into the human embryonic kidney 293 (QBI-293A) cells by Lipofectaimne2000, leading to formation of the recombinant adenoviruses Ad-LIF-polyA+promoter△-IL-24(Ad-LIF-IL-24) co-expressing LIF and IL-24. The most sensitive cell and the best MOI of Ad-LIF-IL-24 was chosen by Ad-LIF-IL-24 infecting SMMC-7721, U251, HT29, A549, HL-60, K562 and WI-38 in vitro. The effect of enhanced growth-suppressing and apoptosis-inducing by Ad-LIF-IL-24 on the tumor cells in vitro were assessed by MTT assay and FCM, and the apoptosis of the cell nucleus were detected by Hochest staining. The expression of apoptosis- and angiogenesis-related genes (bcl-2、bax、ICE、p53 and HIF-1α) and the Cleaved Caspase3 in U251 glioma cells was determined by RT-PCR and Western blotting, respectively.
Results: The adenoviral vector co-expressing LIF and IL-24, Ad-LIF- polyA+promoter△-IL-24, was successfully constructed. More than 95% of theses tumor cells (SMMC-7721, U251, HT29, and A549) and WI-38 cells were infected by Ad-LIF-IL-24 at MOI of 50, whereas HL-60 and K562 cells were hardly infected. The growth of U251 glioma cells was significantly inhibited by Ad-LIF-IL-24 at MOI of 100. Ad-LIF-IL-24- mediated LIF and IL-24 co-expression significantly inhibited U251 glioma cells growth, induced cells apoptosis, exhibiting additive effect. Ad-LIF-IL-24 significantly up-regulated the expression of ICE、bax、p53, and Cleaved Caspase-3 and down-regulated the expression of bcl-2 and HIF-1α.
Conclusion: The adenoviral vector co-expressing LIF and IL-24 (Ad-LIF-IL-24) was successfully constructed. Ad-LIF-IL-24 had significant additive effect in suppressing U251 glioma cells growth and inducing cells apoptosis in vitro. Ad-LIF-IL -24 can up-regulate the expression of ICE、bax、p53 and down-regulate Bcl-2 resulting activation of Caspase-3 and down-regulate the expression of angiogenesis-related gene HIF-1αto exhibit significantly anti-tumor effect on U251 glioma cells in vitro .
引文
[1]郝希山.生物治疗-肿瘤治疗的新希望.中国医药生物技术,2008,3(6):401
[2] Rosenberg SA.Gene therapy for cancer [clinical conference] [J]. JAMA. 1992,268(17): 2416- 2419.
[3]赵新汉,田方,王志宇.肿瘤基因治疗载体的研究现状和展望.现代肿瘤医学, 2007, 15(12):1879-82
[4] Jiang H, Lin JJ, Fisher PB. et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 1995 Dec 21; 11(12):2477-86.
[5] Caudell EG, Mumm JB, Grimm EA. et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002 Jun 15; 168(12):6041-6.
[6] Fickenscher H, H?r S, Sticht H. et al. The interleukin-10 family of cytokines. Trends Immunol. 2002 Feb; 23(2):89-96.
[7] Huang EY, Madireddi MT, Fisher PB. et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene. 2001 Oct 25;20(48):7051-63.
[8] Inoue S, Branch CD, Ramesh R. et al. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther. 2005 Oct;12(4):707-15.
[9] Nishikawa T, Ramesh R, Meyn RE. et al. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther. 2004 Jun;9(6):818-28.
[10] Ramesh R, Mhashilkar AM, Chada S. et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 2003 Aug 15; 63(16):5105-13.
[11] Fisher PB. Is mda-7/IL-24 a "magic bullet" for cancer? Cancer Res. 2005 Nov 15;65(22):10128-38.
[12] Eager R, Harle L, Nemunaitis J. Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert Opin Biol Ther. 2008 Oct; 8(10):1633-43.
[13] Tomid M , Yamamoto—Yamaguch Y, Hozumi M. Purification of a factor inducing differentiation of mouse myeloid leukemic M 1 cells from conditioned medium of mouse fibroblast L929cells.J Biol Chem, 1984, 259:10978—10982.
[14] Gearing DP. Leukemia inhibitory factor and its receptor [J]. Adv Immuno1, 1993, 53:37-58.
[15]李明堂,付玉,闫东君. LIF:一种多功能的细胞因子[J].中国实验诊断学, 2007, 7(11): 987-990.
[16] Chodorowska G. Glowacka A. Tomczyk M. Leukemia inhibitory factor (LIF) and its biological activity. Annales Universitatis Mariae Curie-Sklodowska-Sectiod-
[16] Medicina. 2004,59(2):189-93.
[17] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, et al. Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695.
[18] Kamohara H , Ogawa M , Ishiko T , et al. Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression[J]. Int J Oncol, 2007, 30(4): 977-83.
[19] Estrov Z , Samal B , Kellokumpu-Lehtinen P , et al. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation[J]. J Interferon Cytokine Res , 1995, 15(10): 905-13.
[20] Pia Klausen, Lone Pedersenl, Jesper Jurlander, et al. Oncostatin M and Interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells [J]. Oncogene, 2000, 19(32): 3675-3683.
[21] Hartmut Halfter , Joachim Kremerskothen , Jurgen Weber , et al. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor[J]. J Neuro Oncol, 1998, 39(1): 1-18.
[22] Friedrich M, H?ss N, St?gbauer F,et al.Complete inhibition of in vivo glioma growth by oncostatin M. J Neurochem. 2001, 76(5):1589-92.
[23] Halfter H, Friedrich M, Resch A,et al.Oncostatin M induces growth arrest byinhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression. Cancer Res. 2006, 66(13):6530-9.
[24] Halfter H, Postert C, Friedrich M,et al.Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells. Brain Res Mol Brain Res. 2000,80(2):198-206
[25]曹慧青,丁金凤.多基因共表达载体的构建策略.国外医学分子生物学分册,2002,24(1):1-4
[1] Jiang H, Lin JJ, Fisher PB. et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, med-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 1995, 11(12): 2477-2486.
[2] Caudell EG, Mumm JB, P oindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. Immunol, 2002,168(12): 6041-6046.
[3] Lebedeva IV, Emdad L, Su ZZ, et al. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience. Oncol, 2007, 31(5): 985-1007
[4] Huang EY, Madireddi MT, Fisher PB, et al.Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 2001, 20(48): 7051-63.
[5] Tomid M , Yamamoto—Yamaguch Y, Hozumi M. Purification of a factor inducing differentiation of mouse myeloid leukemic M 1 cells from conditioned medium of mouse fibroblast L929cells.J Biol Chem, 1984, 259: 10978-10982
[6] Gearing DP. Leukemia inhibitory factor and its receptor [J]. Adv Immunol, 1993, 53: 37-58
[7] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, et al. Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695
[8]曹慧青,丁金凤.多基因共表达载体的构建策略.国外医学分子生物学分册,2002,24(1): 1-4
[9]赵新汉,田方,王志宇.肿瘤基因治疗载体的研究现状和展望.现代肿瘤医学, 2007, 15(12): 1879-82
[10] Roy L, Holle W, Wanger, X. Efficient translation and apoptosis by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro. Anticancer Res, 2002, 22: 3185-3189
[11] Tong-Chuan He, Shibin Zhou, Luis T, et al. A simplified system for generation recombinant adenoviruses. Proc Natl Acad Sci USA,1998, 95: 2509-2514
[12] Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell. 1984, 39(3 Pt 2):449-67.
[13] Emerman M, Temin HM. Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol Cell Biol. 1986 Mar; 6(3): 792-800.
[14] Emerman M, Temin HM. Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res. 1986 Dec 9; 14(23): 9381-96.
[15] Dougherty JP, Temin HM. High mutation rate of a spleen necrosis virus-based retrovirus vector. Mol Cell Biol. 1986 Dec;6(12): 4387-95.
[16] Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature. 1988 Jul 28; 334(6180): 320-5.
[17] Hellen CU, Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev. 2001 Jul 1; 15(13): 1593-612.
[18] G?ken J, Jiang J, Daniel K, van Berkel E, Hughes C, Kuiper M, Darling D, Tavassoli M, Galea-Lauri J, Ford K, Kemeny M, Russell S, Farzaneh F. Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron. Gene Ther. 2000 Dec; 7(23): 1979-85.
[19] Sáiz JC, CairóJ, Medina M, Zuidema D, Abrams C, Belsham GJ, Domingo E, Vlak JM. Unprocessed foot-and-mouth disease virus capsid precursor displays discontinuous epitopes involved in viral neutralization. J Virol. 1994, 68(7): 4557-64.
[20] Carrillo C, Tulman ER, Delhon G, Lu Z, Carreno A, Vagnozzi A, Kutish GF, Rock DL. Comparative genomics of foot-and-mouth disease virus. J Virol. 2005 May; 79(10): 6487-504.
[21] Ryan MD, Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J. 1994 Feb 15; 13(4):928-33.
[22] De Felipe P, Martín V, Cortés ML, Ryan M, Izquierdo M. Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Ther. 1999 Feb; 6(2): 198-208.
[1]赵新汉,田方,王志宇.肿瘤基因治疗载体的研究现状和展望.现代肿瘤医学,2007,15(12):1879-82
[2] Bergelson JM,Cunningham JA,Droguett G,et al.Isolation of acommon receptor for Coxsackie viruses and adenoviruses 2 and 5[J].Science,1997,275(53o4):1320-1323.
[3] Marsee DK,Vadysirisack DD,Morrison CD,et al. Variable expression of coxsackie-adenovirus receptor in thyroid tumors:Implications for adenoviral gene therapy[J].Thyroid,2005,15(9):977-987.
[4] Nalbantoglu J,Pari G,Karpati G,et al.Expression ofthe primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells[J].Hum Gene Ther,1999,10 (6):1009-101
[5] Kim M,Zinn KR,Bamett BG,et al.The therapeutic efficacy ofadenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells[J].Eur J Cancer,2002,38(14):1917-1926.
[6] Lebedeva IV, emdad L, Su ZZ, et al. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience. Oncol, 2007, 31(5): 985-1007
[7] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, et al. Leuk- emia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695
[8] Jiang H, Lin JJ, Su ZZ, et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, med-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 1995,11(12): 2477-2486.
[9] CaudellE G, Mumm JB, P oindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immuno stimulatory activity and is designated IL-24. Immunol, 2002, 168(12): 6041-6046.
[10] Huang EY, Madireddi MT, Fisher PB, et al.Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated(mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 2001, 20(48): 7051-63.
[11] Xiong J, Peng ZL, Tan X, et al. Effect of adenovirus-mediated mda-7/IL-24 gene infection on apoptosis of drug-resistant human ovarian cancer cell lines OVCAR-3 and OVCAR-8/TR[J]. Ai Zheng, 2007, 26(4)371-376.
[12] Sieger KA, Mhashilkar AM, Stewart A, et al.The tumor suppressor activity of mda-7/IL-24 is mediated by intracellular protein expression in NSCLC cells [J].Mol Ther, 2004, 9(3):355-367.
[13] Chen WY, Cheng YT, Lei HY, et al. IL-24 inhibits the growth of hepatoma cells in vivo [J].Gene and Immunity, 2005, 6(6):493-499.
[14] Su ZZ, Lebedeva IV, Sarkar D, et al.Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-XL or bcl-2 [J]. Oncogene, 2006, 25(16):2339-2348.
[15] Mahasreshti PJ, kataram M, Wu H, et al.Ovarian cancer targeted adenoviral- mediated mda-7/IL-24 gene therapy [J].Gynecologic Oncology, 2006, 100(3):521-532.
[16] Lebedeva IV, Su ZZ, Sarkar D, et al.Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis [J]. Oncogene, 2005, 24(4):585-596.
[17] Yacoub A, Mitchell C, Dent P. et al. Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo. Clin Cancer Res. 2003 Aug 15; 9(9):3272-81.
[18] Chodorowska G. Glowacka A. Tomczyk M. Leukemia inhibitory factor (LIF) and its biological activity. Annales Universitatis Mariae Curie-Sklodowska-Sectiod- Med- icina. 2004,59(2):189-93
[19]李明堂,付玉,闫东君. LIF:一种多功能的细胞因子.中国实验诊断学, 2007, 11(7):987-990
[20] Tomid M , Yamamoto-Yamaguch Y, Hozumi M. Purification of a factor inducing differentiation of mouse myeloid leukemic M 1 cells from conditioned medium of mouse fibroblast L929cells.J Biol Chem, 1984, 259:10978-10982
[21] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, etal. Leuke- mia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695
[22] Hartmut Halfter , Joachim Kremerskothen , Jurgen Weber , et al. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor[J]. J Neuro Oncol, 1998, 39(1): 1-18.8
[1] Babcock MA, Kostova FV, Maria BL, et al. Tumors of the central nervous system: clinical aspects, molecular mechanisms, unanswered questions, and future research directions.J Child Neurol. 2008 Oct; 23(10):1103-21.
[2] Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol. 2008 Nov; 65(11):1419-24
[3] Ullrich RT, Kracht LW, Jacobs AH.Neuroimaging in patients with gliomas.Semin Neurol. 2008 Sep; 28(4):484-94.
[4] Stewart L A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 2002, 359(9311):1011
[5] Castro MG, Cowen R, Williamson IK, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther, 2003, 98(1): 71-108.
[6] Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiform. Cancer Res, 2003, 63(10): 2462-2469.
[7] Jiang H, Lin JJ, Su ZZ, et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, med-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 1995,11(12): 2477-2486.
[8] Huang EY, Madireddi MT, Fisher PB, et al.Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 2001, 20(48): 7051-63.
[9] Fisher PB. Is mda-7/IL-24 a "magic bullet" for cancer? Cancer Res. 2005 Nov 15; 65(22):10128-38.
[10] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, et al. Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695
[11] Hartmut Halfter , Joachim Kremerskothen , Jurgen Weber , et al. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor[J]. J Neuro Oncol, 1998, 39(1): 1-18.
[12] Richards LJ, Kilpatrick TJ, Dutton R, et al. Leukaemia inhibitory factor or related factors promote the differentiation of neuronal and astrocytic precursors within the developing murine spinal cord [J]. Eur J Neurosci, 1996 , 8(2): 291-9
[13] Halfter H, Friedrich M, Resch A,et al.Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression. Cancer Res. 2006, 66(13):6530-9.
[14] Davis ID. Kiers L. MacGregor L. Quinn M. Arezzo J. Green M. Rosenthal M. Chia M. Michael M. Bartley P. Harrison L. Daly M. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.[see comment]. Clinical Cancer Research. 2005 ,11(5):1890-8
[15] Tomid M , Yamamoto-Yamaguch Y, Hozumi M. Purification of a factor inducing differentiation of mouse myeloid leukemic M 1 cells from conditioned medium of mouse fibroblast L929cells.J Biol Chem, 1984, 259:10978—10982
[16] Kamohara H, Ogawa M, Ishiko T, et al.Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression. Int J Oncol. 2007,30(4):977-83
[17] García-Tu?ón I, Ricote M, Ruiz A, Royuela M.et al. OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative).Cancer Invest. 2008 Apr-May; 26(3):222-9.
[18] Pia Klausen, Lone Pedersenl, Jesper Jurlander , et al.Oncostatin M and Interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells。Oncogene, 2000, 19:3675-3683
[19] Laura K, Shcaefer, Schaefer, et al. Activation of Stat3 and Stat1 DNA binding and transcriptional activity in human brain tumor cell lines by gp130 cytokines. Cellular Signaling, 2000, 12: 143-151
[20] Chen WY, Cheng YT, Lei HY, et al. IL-24 inhibits the growth of hepatoma cells in vivo[J].Gene and Immunity,2005,6(6):493-499.
[21] Su ZZ, Lebedeva IV, Sarkar D, et al.Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-XL or bcl-2 [J]. Oncogene,2006, 25(16):2339-2348.
[22] Mahasreshti PJ, kataram M, Wu H, et al.Ovarian cancer targeted adenoviral- mediated mda-7/IL-24 gene therapy [J].Gynecologic Oncology, 2006, 100(3):521-532.
[23] Lebedeva IV, Su ZZ, Sarkar D, et al.Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis [J]. Oncogene, 2005, 24(4):585-596.
[24] Yacoub A, Mitchell C, Dent P. et al. Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo. Clin Cancer Res. 2003 Aug 15; 9(9):3272-81.
[25] CaudellE G, Mumm JB, P oindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. Immunol, 2002, 168(12): 6041-6046.
[26] Huang EY, Madireddi MT, Fisher PB, et al.Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 2001, 20(48): 7051-63.
[27] Oida Y, Gopalan B, Miyahara R, et al.Sulindac enhances adenoviral vector expressing mda-7/IL-24 mediated apoptosis I human lung cancer [J].Mol Cancer Ther, 2005, 4(2):291-304.
[28] Sarkar D,Su ZZ,Lebedeva IV,et al.MDA-7(IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of P38MAPK[J].Proc Natl Acad Sci USA, 2002, 99(15):10054-10059.
[29] Pataer A, Vorburger SA, Barber GN, et al.Adenoviral transfer of the melanoma differentiation-associated gene 7(mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR) [J]. Cancer Res, 2002, 62(8):2239-2243.
[30] Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996 Jul 12; 86(1):147-57.
[31] Hengartner MO. The biochemistry of apoptosis. Nature. 2000 Oct 12; 407(6805):770-6.
[32] Cosulich SC, Savory PJ, Clarke PR. Bcl-2 regulates amplification of caspase activation by cytochrome c. Curr Biol. 1999 Feb 11; 9(3):147-50.
[33] Folkman J. Fighting cancer by attacking its blood supply. Sci Am. 1996 Sep; 275(3):150-4.
[34] Wang GL.Semenza GL.Characterization of hypoxia-inducible factor1 and regulation of DNA blinding activity by hypoxia. J Biol Chem ,1993,268:21513- 21518
[35] Erez N,M ilyavsky M ,Eliam R,et al.Expression of prolyl-hydroxylase- 1(PHD1/EGLN2)suppresses hypoxia inducible factor-1 alpha activation and inhibits tumor growth.Cancer Res,2003,63:8777- 8783
[36] Josko J,Mazurek M.Transcription factors having impact on vasclllar endothelial growth factor(VEGF)gene expression in angiogenesis. M ed Sci M onit,2004,10: 89-98
[37] Na X ,W u G ,Ryan CK ,et al.Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tum or suppressor gene mutations and hypoxia inducible factor-1 alpha expression in real eell carcinomas.J Urol,2003,170:588-592
[38] Maxwell PH。Pugh CW。Ratcliffe PJ.Activation of the HIF pathway in cancer.Curr Opin Genet Dev,2001,11:293- 299
[39] Haddad JJ.Oxygen sensing and oxidantredox-related pathways.Biochem Biophys Res comm un,2004,316:969- 977
[40] Wang GL。Jing BH,Ruc EA ,et a1.Hypoxia-induced factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by celluar tension[J].Proc Natl Acad Sci USA,1995,92(12):5510-5514
[41] Korkolopoulou P,Patsouris E,Konstantinidou AE,et a1.Hypoxia inducible Factor-alpha/vascular Endothelial Growth factor axis in astrocytomas Associations with microvessel morphometry,proliferation and prognosis.Neuropathol Appl Neurobiol,2004;30(3):267-78
[1] Roth, J.A, Cristiano, R. J. Gene therapy for cancer:What have we done and where are we going? Nat1. Cancer Inst, 1997, 89:21-39
[2] Chamberlain MC. Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med, 1998, 168(2):114-120
[3] Lang FF, Yung W K A, Saw aya R, et a1. Adernovirus mediated p53 gene therapy for human gliomas. Neurosurgery, 1999, 45(5):1093-1104
[4] Furyo J, Gomez MC, Yung W K, et a1. Overexpression of E2F1 in glioma a triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med, 1998, 4(6):685-689
[5] Merzak A, Pilkington G.J. Molecular and cellular pathology of intrinsic brain tumors. Cancer Metastasis Rev, 1997, 16:155-177
[6] Merzak A. et a1. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factorβ1.Br. J. Cancer, 1994, 70:199-203
[7] Puzzilli F, Ruggeri A, Mastronardi L, et al. Long-term survival in cerebral glioblastoma. Case report and critical review of the literature. Tumori, 1998, 84(1):69
[8] Kaba S E, Kyritsis A P. Recognition and management of gliomas. Drugs, 1997, 53:235-244
[9] Ojemann J G. et a1. Preserved function in brain invaded by tumor. Neurosurgery, 1996, 39:253 -258
[10] Stewart L A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 2002, 359(9311):1011
[11] Collins,V.P.and James,C.D.Gene and chromosomal alterations associated with the development of human iomas. FASEB J,1993,7:926-930
[12] Furnari F B, Huang H J, Cavenee W K. Genetics and malignant progression of human brain tumors. Cancer Surv, 1995, 25:233 -275
[13] Kleihues P, Ohgaki H. Genetics of glioma progression and the definition ofprimary and secondary glioblastoma. Brain Pathol, 1997, 7:1131-1136
[14] Fueyo J, Gomez-Manzano C, Yung W K A. et a1. The funcional role of tumor suppressor genes in gliomas: Clues for future therapeutic strategies. Neurology, 1998, 51:1250-1255
[15] Gomez-Manzano C, Fueyo J, Kyritsis A P. et a1. Tumor suppressor gene therapy for brain tumors.In“Ge ne Transfer and Therapy for Neurological Disorders”(A. E. Chiocca and X. Breakefield, Eds.), Human Press, 1998, Totowa,NJ
[16] Kurozumi K, Tamiya T, Ono Y, et a1.Apoptosis induction with 5-fluorocytosine/ cytosine deaminase gene therapy for human malignant glioma cells medlared bv adenovirus [J]. J Neurooncol, 2004, 66(1-2): 117-127.
[17] Lu SQ, LiuYS, Yang H. et al. Effects of CD/5-Fc suicide gene therapy system on human malignant glioma cels in vitro [J].Zhong Nan Da Xue Xue Bao Yi Xue Bai, 2004, 29(2):174, 176, l80
[18] Okada T, Caplen NJ, Ramsey WJ. et al. In situ generation of pseudo-typed retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo [J]. J Gene Med, 2004, 6(3):288-299.
[19] Moriuchi S,G1orieso JC,MarunoM,et a1.Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinasel [J]. Cancer Gene Ther, 2005, 12(5):487-496.
[20] Mearadji A,Breeman W, Hoiland L,et al.Somatoasatatin receptor gene therapy combined with targeted therapy with radiolabeledd octreotide:a new treatment for liver metastases[J].Ann Surg, 2002,236(6):722-728.
[21] Ammerpohl O,Thormeyer D,Khan Z,et al.HDACi phenylbutyrate in creases bystander killing of HSV-tk transfected glioma cells [J]. Bio-chem Biophys Res Commun,2004,324(1):8-14.
[22] Colombo F,Barzon L,Franchin E,etal.Combined HSV-TK/IL-2 gene therapy in patients with recrurrent glioblastoma muhiforme:biological and clinical resuhs [J].Cancer Gene Ther,2005,12(10):835-848.
[23] NakabaraN,Polack IF,Storkus WJ,et al.Effective induction of antigliomacytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells[J].Cancer Gene Ther, 2003,l0(7):549-558.
[24] Lan P,Dong C,Qi Y,et al.Gene therapy for mice sarcoma with oncolytic herpes simplex virus-l lacking the apoptosis-inhibiting gene, icp34.5[J].J Biochem Mol Biol,2003,36(4):379-386.
[25] Mukheljee J,Ghosh A,Sarkar P,et al.Immunothempy with T11TS/S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status [J].Anticancer Res,2005,25(4):2905-2519.
[26] Zhu X,Lu C,Xiao B,et al.An experimental study of dendritic cells mediated immunotherapy against intracranial glioma sin rats[J].J Neuro oncol,2005,74(1):9-17.
[27]董震,牛洪泉,董芳永,等.脑胶质瘤患者自体免疫治疗前后T细胞亚群的变化[J].肿瘤防治研究,2004,20(2):131.
[28] Gil-Perotin S,Marln-Husstege M,LI J,et a1.Loss of p53 induces change in the behavior of subventricular zone cells:implication for the genesis of al tumors[J].J Neurosci,2006,26(4):1107-1116.
[29] Senatus PB, LI Y,Mandigo C,et al.Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma, a cells in vitro and in vivo by a p53 COOH-terminal peptide [J].Mol Cancer Ther,2006,5(1):20-28.
[30] NashlmotoT,Komata T,KanzAtwa T,et a1.Mild hyperthermia plus adenoviral p53 over-expression additively inhibits the viability of human malignant glioma cells [J]. Int J Hyperthermia,2005,21(7):615-629.
[31] Michiue H,Tomizawa K,Matsushita M,et al.Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells [J].FEBs Lett,2005,579(18):3965-3969.
[32] Mitlianga PC, Sioka C,Vartholonmtos G,et al.p53 enhances the Delta-24 conditionally replicative adenovirus anti-glioma effect[J].Oncol Rep,2006,l5(1):149-153.
[33] Ito H,Kanzawa T,Miyos T,et al.Therapeutic efficacy of PUMA fof malignant glioma cells regardless of p53 status [J].Hum Gene ther,2005,16(6):685-698.
[34] Matsumoto Y,Miyake K,Kunishio K,et al.Reduction of expression of the multidrug resistance protein(MRP)l in glioma cells by antisense phesphomthioate oligenuclcotides [J].J Med Invest,2004,51(3-4):194-201.
[35] Rittierodt M,Tschemig T,Hrada K,et al.Modulation of multidrug-resistance- associated P-glycoprotein in human U87MG and HUV-ECC cells with antisense oligedeoxynucleotides to MDR1 mRNA[J]. Patho-bidogy,2004,71(3):123-128.
[36]郭华,张庆林,王成伟,等.反义肽核酸阻断人神经母细胞瘤多药耐药相关蛋白P-糖蛋自的表达[J].中国医学科学院学报,2005,27(3):300-304.
[37] Leirdal M,Sioud M.Gene-array analysis of glioma cells after treatment with an anti-PKC alpha siRNA:a general protocol [J].Methods in Mol Biol,2004,252:493-500.
[38] Fan QW,Weiss WA.RNA interference against a glioma-derived allele of EGFR induces blockade at G2M [J].Oncogene, 2005, 24(5): 829-837.
[39] Hatano M,Mizuno M,Yoahida J.Enhancement of C2-ceramide antitumor activity by small interfering RNA on X chromosome linked inhibitor of apoptosis protein in resistant human glioma cells[J].J Neurosurg,2004,101(1):119-127.
[40] Gondi CS,Lakka SS,Dinh DH,et al.RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas [J]. Oncogene, 2004, 23(52): 8486-8496.
[41]杨翔云,赖小刚,张勇,等.干扰CIC2基因表达对胶质瘤BT-325细胞生长的影响[J].中国康复理论与实践,2006,12 (5): 378-380.
[42]杨翔云,赖小刚.张勇,等.siRNA干扰CIC-2表达对人胶质瘤U87细胞增殖的抑作用[J].癌症,2006,25(7): 805-810.
[43]赵澎.胡微,张亚卓,等.RNA干扰技术逆转神经胶质瘤细胞多药耐药性[J].中华肿瘤杂志,2006,28(3):183-187.
[44]孙卫东,于如同,马衍刚.短发夹RNA沉默hTERT基因抑制裸鼠皮下人脑胶质瘤生长的实验研究[J].徐州医学院学报,2007,27(5):290-294.
[2] Rosenberg SA.Gene therapy for cancer [clinical conference] [J]. JAMA. 1992,268(17): 2416- 2419.
[3]赵新汉,田方,王志宇.肿瘤基因治疗载体的研究现状和展望.现代肿瘤医学, 2007, 15(12):1879-82
[4] Jiang H, Lin JJ, Fisher PB. et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 1995 Dec 21; 11(12):2477-86.
[5] Caudell EG, Mumm JB, Grimm EA. et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002 Jun 15; 168(12):6041-6.
[6] Fickenscher H, H?r S, Sticht H. et al. The interleukin-10 family of cytokines. Trends Immunol. 2002 Feb; 23(2):89-96.
[7] Huang EY, Madireddi MT, Fisher PB. et al. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene. 2001 Oct 25;20(48):7051-63.
[8] Inoue S, Branch CD, Ramesh R. et al. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther. 2005 Oct;12(4):707-15.
[9] Nishikawa T, Ramesh R, Meyn RE. et al. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther. 2004 Jun;9(6):818-28.
[10] Ramesh R, Mhashilkar AM, Chada S. et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 2003 Aug 15; 63(16):5105-13.
[11] Fisher PB. Is mda-7/IL-24 a "magic bullet" for cancer? Cancer Res. 2005 Nov 15;65(22):10128-38.
[12] Eager R, Harle L, Nemunaitis J. Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert Opin Biol Ther. 2008 Oct; 8(10):1633-43.
[13] Tomid M , Yamamoto—Yamaguch Y, Hozumi M. Purification of a factor inducing differentiation of mouse myeloid leukemic M 1 cells from conditioned medium of mouse fibroblast L929cells.J Biol Chem, 1984, 259:10978—10982.
[14] Gearing DP. Leukemia inhibitory factor and its receptor [J]. Adv Immuno1, 1993, 53:37-58.
[15]李明堂,付玉,闫东君. LIF:一种多功能的细胞因子[J].中国实验诊断学, 2007, 7(11): 987-990.
[16] Chodorowska G. Glowacka A. Tomczyk M. Leukemia inhibitory factor (LIF) and its biological activity. Annales Universitatis Mariae Curie-Sklodowska-Sectiod-
[16] Medicina. 2004,59(2):189-93.
[17] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, et al. Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695.
[18] Kamohara H , Ogawa M , Ishiko T , et al. Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression[J]. Int J Oncol, 2007, 30(4): 977-83.
[19] Estrov Z , Samal B , Kellokumpu-Lehtinen P , et al. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation[J]. J Interferon Cytokine Res , 1995, 15(10): 905-13.
[20] Pia Klausen, Lone Pedersenl, Jesper Jurlander, et al. Oncostatin M and Interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells [J]. Oncogene, 2000, 19(32): 3675-3683.
[21] Hartmut Halfter , Joachim Kremerskothen , Jurgen Weber , et al. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor[J]. J Neuro Oncol, 1998, 39(1): 1-18.
[22] Friedrich M, H?ss N, St?gbauer F,et al.Complete inhibition of in vivo glioma growth by oncostatin M. J Neurochem. 2001, 76(5):1589-92.
[23] Halfter H, Friedrich M, Resch A,et al.Oncostatin M induces growth arrest byinhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression. Cancer Res. 2006, 66(13):6530-9.
[24] Halfter H, Postert C, Friedrich M,et al.Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells. Brain Res Mol Brain Res. 2000,80(2):198-206
[25]曹慧青,丁金凤.多基因共表达载体的构建策略.国外医学分子生物学分册,2002,24(1):1-4
[1] Jiang H, Lin JJ, Fisher PB. et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, med-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 1995, 11(12): 2477-2486.
[2] Caudell EG, Mumm JB, P oindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. Immunol, 2002,168(12): 6041-6046.
[3] Lebedeva IV, Emdad L, Su ZZ, et al. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience. Oncol, 2007, 31(5): 985-1007
[4] Huang EY, Madireddi MT, Fisher PB, et al.Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 2001, 20(48): 7051-63.
[5] Tomid M , Yamamoto—Yamaguch Y, Hozumi M. Purification of a factor inducing differentiation of mouse myeloid leukemic M 1 cells from conditioned medium of mouse fibroblast L929cells.J Biol Chem, 1984, 259: 10978-10982
[6] Gearing DP. Leukemia inhibitory factor and its receptor [J]. Adv Immunol, 1993, 53: 37-58
[7] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, et al. Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695
[8]曹慧青,丁金凤.多基因共表达载体的构建策略.国外医学分子生物学分册,2002,24(1): 1-4
[9]赵新汉,田方,王志宇.肿瘤基因治疗载体的研究现状和展望.现代肿瘤医学, 2007, 15(12): 1879-82
[10] Roy L, Holle W, Wanger, X. Efficient translation and apoptosis by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro. Anticancer Res, 2002, 22: 3185-3189
[11] Tong-Chuan He, Shibin Zhou, Luis T, et al. A simplified system for generation recombinant adenoviruses. Proc Natl Acad Sci USA,1998, 95: 2509-2514
[12] Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell. 1984, 39(3 Pt 2):449-67.
[13] Emerman M, Temin HM. Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol Cell Biol. 1986 Mar; 6(3): 792-800.
[14] Emerman M, Temin HM. Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res. 1986 Dec 9; 14(23): 9381-96.
[15] Dougherty JP, Temin HM. High mutation rate of a spleen necrosis virus-based retrovirus vector. Mol Cell Biol. 1986 Dec;6(12): 4387-95.
[16] Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature. 1988 Jul 28; 334(6180): 320-5.
[17] Hellen CU, Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev. 2001 Jul 1; 15(13): 1593-612.
[18] G?ken J, Jiang J, Daniel K, van Berkel E, Hughes C, Kuiper M, Darling D, Tavassoli M, Galea-Lauri J, Ford K, Kemeny M, Russell S, Farzaneh F. Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron. Gene Ther. 2000 Dec; 7(23): 1979-85.
[19] Sáiz JC, CairóJ, Medina M, Zuidema D, Abrams C, Belsham GJ, Domingo E, Vlak JM. Unprocessed foot-and-mouth disease virus capsid precursor displays discontinuous epitopes involved in viral neutralization. J Virol. 1994, 68(7): 4557-64.
[20] Carrillo C, Tulman ER, Delhon G, Lu Z, Carreno A, Vagnozzi A, Kutish GF, Rock DL. Comparative genomics of foot-and-mouth disease virus. J Virol. 2005 May; 79(10): 6487-504.
[21] Ryan MD, Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J. 1994 Feb 15; 13(4):928-33.
[22] De Felipe P, Martín V, Cortés ML, Ryan M, Izquierdo M. Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Ther. 1999 Feb; 6(2): 198-208.
[1]赵新汉,田方,王志宇.肿瘤基因治疗载体的研究现状和展望.现代肿瘤医学,2007,15(12):1879-82
[2] Bergelson JM,Cunningham JA,Droguett G,et al.Isolation of acommon receptor for Coxsackie viruses and adenoviruses 2 and 5[J].Science,1997,275(53o4):1320-1323.
[3] Marsee DK,Vadysirisack DD,Morrison CD,et al. Variable expression of coxsackie-adenovirus receptor in thyroid tumors:Implications for adenoviral gene therapy[J].Thyroid,2005,15(9):977-987.
[4] Nalbantoglu J,Pari G,Karpati G,et al.Expression ofthe primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells[J].Hum Gene Ther,1999,10 (6):1009-101
[5] Kim M,Zinn KR,Bamett BG,et al.The therapeutic efficacy ofadenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells[J].Eur J Cancer,2002,38(14):1917-1926.
[6] Lebedeva IV, emdad L, Su ZZ, et al. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience. Oncol, 2007, 31(5): 985-1007
[7] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, et al. Leuk- emia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695
[8] Jiang H, Lin JJ, Su ZZ, et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, med-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 1995,11(12): 2477-2486.
[9] CaudellE G, Mumm JB, P oindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immuno stimulatory activity and is designated IL-24. Immunol, 2002, 168(12): 6041-6046.
[10] Huang EY, Madireddi MT, Fisher PB, et al.Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated(mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 2001, 20(48): 7051-63.
[11] Xiong J, Peng ZL, Tan X, et al. Effect of adenovirus-mediated mda-7/IL-24 gene infection on apoptosis of drug-resistant human ovarian cancer cell lines OVCAR-3 and OVCAR-8/TR[J]. Ai Zheng, 2007, 26(4)371-376.
[12] Sieger KA, Mhashilkar AM, Stewart A, et al.The tumor suppressor activity of mda-7/IL-24 is mediated by intracellular protein expression in NSCLC cells [J].Mol Ther, 2004, 9(3):355-367.
[13] Chen WY, Cheng YT, Lei HY, et al. IL-24 inhibits the growth of hepatoma cells in vivo [J].Gene and Immunity, 2005, 6(6):493-499.
[14] Su ZZ, Lebedeva IV, Sarkar D, et al.Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-XL or bcl-2 [J]. Oncogene, 2006, 25(16):2339-2348.
[15] Mahasreshti PJ, kataram M, Wu H, et al.Ovarian cancer targeted adenoviral- mediated mda-7/IL-24 gene therapy [J].Gynecologic Oncology, 2006, 100(3):521-532.
[16] Lebedeva IV, Su ZZ, Sarkar D, et al.Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis [J]. Oncogene, 2005, 24(4):585-596.
[17] Yacoub A, Mitchell C, Dent P. et al. Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo. Clin Cancer Res. 2003 Aug 15; 9(9):3272-81.
[18] Chodorowska G. Glowacka A. Tomczyk M. Leukemia inhibitory factor (LIF) and its biological activity. Annales Universitatis Mariae Curie-Sklodowska-Sectiod- Med- icina. 2004,59(2):189-93
[19]李明堂,付玉,闫东君. LIF:一种多功能的细胞因子.中国实验诊断学, 2007, 11(7):987-990
[20] Tomid M , Yamamoto-Yamaguch Y, Hozumi M. Purification of a factor inducing differentiation of mouse myeloid leukemic M 1 cells from conditioned medium of mouse fibroblast L929cells.J Biol Chem, 1984, 259:10978-10982
[21] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, etal. Leuke- mia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695
[22] Hartmut Halfter , Joachim Kremerskothen , Jurgen Weber , et al. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor[J]. J Neuro Oncol, 1998, 39(1): 1-18.8
[1] Babcock MA, Kostova FV, Maria BL, et al. Tumors of the central nervous system: clinical aspects, molecular mechanisms, unanswered questions, and future research directions.J Child Neurol. 2008 Oct; 23(10):1103-21.
[2] Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol. 2008 Nov; 65(11):1419-24
[3] Ullrich RT, Kracht LW, Jacobs AH.Neuroimaging in patients with gliomas.Semin Neurol. 2008 Sep; 28(4):484-94.
[4] Stewart L A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 2002, 359(9311):1011
[5] Castro MG, Cowen R, Williamson IK, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther, 2003, 98(1): 71-108.
[6] Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiform. Cancer Res, 2003, 63(10): 2462-2469.
[7] Jiang H, Lin JJ, Su ZZ, et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, med-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 1995,11(12): 2477-2486.
[8] Huang EY, Madireddi MT, Fisher PB, et al.Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 2001, 20(48): 7051-63.
[9] Fisher PB. Is mda-7/IL-24 a "magic bullet" for cancer? Cancer Res. 2005 Nov 15; 65(22):10128-38.
[10] Hidenobu KAMOHARA, Yoshihiro MASUDA, Michio OGAWA, et al. Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways [J]. Int J Cancer , 1997 , 72 (4): 687–695
[11] Hartmut Halfter , Joachim Kremerskothen , Jurgen Weber , et al. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor[J]. J Neuro Oncol, 1998, 39(1): 1-18.
[12] Richards LJ, Kilpatrick TJ, Dutton R, et al. Leukaemia inhibitory factor or related factors promote the differentiation of neuronal and astrocytic precursors within the developing murine spinal cord [J]. Eur J Neurosci, 1996 , 8(2): 291-9
[13] Halfter H, Friedrich M, Resch A,et al.Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression. Cancer Res. 2006, 66(13):6530-9.
[14] Davis ID. Kiers L. MacGregor L. Quinn M. Arezzo J. Green M. Rosenthal M. Chia M. Michael M. Bartley P. Harrison L. Daly M. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.[see comment]. Clinical Cancer Research. 2005 ,11(5):1890-8
[15] Tomid M , Yamamoto-Yamaguch Y, Hozumi M. Purification of a factor inducing differentiation of mouse myeloid leukemic M 1 cells from conditioned medium of mouse fibroblast L929cells.J Biol Chem, 1984, 259:10978—10982
[16] Kamohara H, Ogawa M, Ishiko T, et al.Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression. Int J Oncol. 2007,30(4):977-83
[17] García-Tu?ón I, Ricote M, Ruiz A, Royuela M.et al. OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative).Cancer Invest. 2008 Apr-May; 26(3):222-9.
[18] Pia Klausen, Lone Pedersenl, Jesper Jurlander , et al.Oncostatin M and Interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells。Oncogene, 2000, 19:3675-3683
[19] Laura K, Shcaefer, Schaefer, et al. Activation of Stat3 and Stat1 DNA binding and transcriptional activity in human brain tumor cell lines by gp130 cytokines. Cellular Signaling, 2000, 12: 143-151
[20] Chen WY, Cheng YT, Lei HY, et al. IL-24 inhibits the growth of hepatoma cells in vivo[J].Gene and Immunity,2005,6(6):493-499.
[21] Su ZZ, Lebedeva IV, Sarkar D, et al.Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-XL or bcl-2 [J]. Oncogene,2006, 25(16):2339-2348.
[22] Mahasreshti PJ, kataram M, Wu H, et al.Ovarian cancer targeted adenoviral- mediated mda-7/IL-24 gene therapy [J].Gynecologic Oncology, 2006, 100(3):521-532.
[23] Lebedeva IV, Su ZZ, Sarkar D, et al.Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis [J]. Oncogene, 2005, 24(4):585-596.
[24] Yacoub A, Mitchell C, Dent P. et al. Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo. Clin Cancer Res. 2003 Aug 15; 9(9):3272-81.
[25] CaudellE G, Mumm JB, P oindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. Immunol, 2002, 168(12): 6041-6046.
[26] Huang EY, Madireddi MT, Fisher PB, et al.Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 2001, 20(48): 7051-63.
[27] Oida Y, Gopalan B, Miyahara R, et al.Sulindac enhances adenoviral vector expressing mda-7/IL-24 mediated apoptosis I human lung cancer [J].Mol Cancer Ther, 2005, 4(2):291-304.
[28] Sarkar D,Su ZZ,Lebedeva IV,et al.MDA-7(IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of P38MAPK[J].Proc Natl Acad Sci USA, 2002, 99(15):10054-10059.
[29] Pataer A, Vorburger SA, Barber GN, et al.Adenoviral transfer of the melanoma differentiation-associated gene 7(mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR) [J]. Cancer Res, 2002, 62(8):2239-2243.
[30] Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996 Jul 12; 86(1):147-57.
[31] Hengartner MO. The biochemistry of apoptosis. Nature. 2000 Oct 12; 407(6805):770-6.
[32] Cosulich SC, Savory PJ, Clarke PR. Bcl-2 regulates amplification of caspase activation by cytochrome c. Curr Biol. 1999 Feb 11; 9(3):147-50.
[33] Folkman J. Fighting cancer by attacking its blood supply. Sci Am. 1996 Sep; 275(3):150-4.
[34] Wang GL.Semenza GL.Characterization of hypoxia-inducible factor1 and regulation of DNA blinding activity by hypoxia. J Biol Chem ,1993,268:21513- 21518
[35] Erez N,M ilyavsky M ,Eliam R,et al.Expression of prolyl-hydroxylase- 1(PHD1/EGLN2)suppresses hypoxia inducible factor-1 alpha activation and inhibits tumor growth.Cancer Res,2003,63:8777- 8783
[36] Josko J,Mazurek M.Transcription factors having impact on vasclllar endothelial growth factor(VEGF)gene expression in angiogenesis. M ed Sci M onit,2004,10: 89-98
[37] Na X ,W u G ,Ryan CK ,et al.Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tum or suppressor gene mutations and hypoxia inducible factor-1 alpha expression in real eell carcinomas.J Urol,2003,170:588-592
[38] Maxwell PH。Pugh CW。Ratcliffe PJ.Activation of the HIF pathway in cancer.Curr Opin Genet Dev,2001,11:293- 299
[39] Haddad JJ.Oxygen sensing and oxidantredox-related pathways.Biochem Biophys Res comm un,2004,316:969- 977
[40] Wang GL。Jing BH,Ruc EA ,et a1.Hypoxia-induced factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by celluar tension[J].Proc Natl Acad Sci USA,1995,92(12):5510-5514
[41] Korkolopoulou P,Patsouris E,Konstantinidou AE,et a1.Hypoxia inducible Factor-alpha/vascular Endothelial Growth factor axis in astrocytomas Associations with microvessel morphometry,proliferation and prognosis.Neuropathol Appl Neurobiol,2004;30(3):267-78
[1] Roth, J.A, Cristiano, R. J. Gene therapy for cancer:What have we done and where are we going? Nat1. Cancer Inst, 1997, 89:21-39
[2] Chamberlain MC. Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med, 1998, 168(2):114-120
[3] Lang FF, Yung W K A, Saw aya R, et a1. Adernovirus mediated p53 gene therapy for human gliomas. Neurosurgery, 1999, 45(5):1093-1104
[4] Furyo J, Gomez MC, Yung W K, et a1. Overexpression of E2F1 in glioma a triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med, 1998, 4(6):685-689
[5] Merzak A, Pilkington G.J. Molecular and cellular pathology of intrinsic brain tumors. Cancer Metastasis Rev, 1997, 16:155-177
[6] Merzak A. et a1. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factorβ1.Br. J. Cancer, 1994, 70:199-203
[7] Puzzilli F, Ruggeri A, Mastronardi L, et al. Long-term survival in cerebral glioblastoma. Case report and critical review of the literature. Tumori, 1998, 84(1):69
[8] Kaba S E, Kyritsis A P. Recognition and management of gliomas. Drugs, 1997, 53:235-244
[9] Ojemann J G. et a1. Preserved function in brain invaded by tumor. Neurosurgery, 1996, 39:253 -258
[10] Stewart L A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 2002, 359(9311):1011
[11] Collins,V.P.and James,C.D.Gene and chromosomal alterations associated with the development of human iomas. FASEB J,1993,7:926-930
[12] Furnari F B, Huang H J, Cavenee W K. Genetics and malignant progression of human brain tumors. Cancer Surv, 1995, 25:233 -275
[13] Kleihues P, Ohgaki H. Genetics of glioma progression and the definition ofprimary and secondary glioblastoma. Brain Pathol, 1997, 7:1131-1136
[14] Fueyo J, Gomez-Manzano C, Yung W K A. et a1. The funcional role of tumor suppressor genes in gliomas: Clues for future therapeutic strategies. Neurology, 1998, 51:1250-1255
[15] Gomez-Manzano C, Fueyo J, Kyritsis A P. et a1. Tumor suppressor gene therapy for brain tumors.In“Ge ne Transfer and Therapy for Neurological Disorders”(A. E. Chiocca and X. Breakefield, Eds.), Human Press, 1998, Totowa,NJ
[16] Kurozumi K, Tamiya T, Ono Y, et a1.Apoptosis induction with 5-fluorocytosine/ cytosine deaminase gene therapy for human malignant glioma cells medlared bv adenovirus [J]. J Neurooncol, 2004, 66(1-2): 117-127.
[17] Lu SQ, LiuYS, Yang H. et al. Effects of CD/5-Fc suicide gene therapy system on human malignant glioma cels in vitro [J].Zhong Nan Da Xue Xue Bao Yi Xue Bai, 2004, 29(2):174, 176, l80
[18] Okada T, Caplen NJ, Ramsey WJ. et al. In situ generation of pseudo-typed retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo [J]. J Gene Med, 2004, 6(3):288-299.
[19] Moriuchi S,G1orieso JC,MarunoM,et a1.Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinasel [J]. Cancer Gene Ther, 2005, 12(5):487-496.
[20] Mearadji A,Breeman W, Hoiland L,et al.Somatoasatatin receptor gene therapy combined with targeted therapy with radiolabeledd octreotide:a new treatment for liver metastases[J].Ann Surg, 2002,236(6):722-728.
[21] Ammerpohl O,Thormeyer D,Khan Z,et al.HDACi phenylbutyrate in creases bystander killing of HSV-tk transfected glioma cells [J]. Bio-chem Biophys Res Commun,2004,324(1):8-14.
[22] Colombo F,Barzon L,Franchin E,etal.Combined HSV-TK/IL-2 gene therapy in patients with recrurrent glioblastoma muhiforme:biological and clinical resuhs [J].Cancer Gene Ther,2005,12(10):835-848.
[23] NakabaraN,Polack IF,Storkus WJ,et al.Effective induction of antigliomacytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells[J].Cancer Gene Ther, 2003,l0(7):549-558.
[24] Lan P,Dong C,Qi Y,et al.Gene therapy for mice sarcoma with oncolytic herpes simplex virus-l lacking the apoptosis-inhibiting gene, icp34.5[J].J Biochem Mol Biol,2003,36(4):379-386.
[25] Mukheljee J,Ghosh A,Sarkar P,et al.Immunothempy with T11TS/S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status [J].Anticancer Res,2005,25(4):2905-2519.
[26] Zhu X,Lu C,Xiao B,et al.An experimental study of dendritic cells mediated immunotherapy against intracranial glioma sin rats[J].J Neuro oncol,2005,74(1):9-17.
[27]董震,牛洪泉,董芳永,等.脑胶质瘤患者自体免疫治疗前后T细胞亚群的变化[J].肿瘤防治研究,2004,20(2):131.
[28] Gil-Perotin S,Marln-Husstege M,LI J,et a1.Loss of p53 induces change in the behavior of subventricular zone cells:implication for the genesis of al tumors[J].J Neurosci,2006,26(4):1107-1116.
[29] Senatus PB, LI Y,Mandigo C,et al.Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma, a cells in vitro and in vivo by a p53 COOH-terminal peptide [J].Mol Cancer Ther,2006,5(1):20-28.
[30] NashlmotoT,Komata T,KanzAtwa T,et a1.Mild hyperthermia plus adenoviral p53 over-expression additively inhibits the viability of human malignant glioma cells [J]. Int J Hyperthermia,2005,21(7):615-629.
[31] Michiue H,Tomizawa K,Matsushita M,et al.Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells [J].FEBs Lett,2005,579(18):3965-3969.
[32] Mitlianga PC, Sioka C,Vartholonmtos G,et al.p53 enhances the Delta-24 conditionally replicative adenovirus anti-glioma effect[J].Oncol Rep,2006,l5(1):149-153.
[33] Ito H,Kanzawa T,Miyos T,et al.Therapeutic efficacy of PUMA fof malignant glioma cells regardless of p53 status [J].Hum Gene ther,2005,16(6):685-698.
[34] Matsumoto Y,Miyake K,Kunishio K,et al.Reduction of expression of the multidrug resistance protein(MRP)l in glioma cells by antisense phesphomthioate oligenuclcotides [J].J Med Invest,2004,51(3-4):194-201.
[35] Rittierodt M,Tschemig T,Hrada K,et al.Modulation of multidrug-resistance- associated P-glycoprotein in human U87MG and HUV-ECC cells with antisense oligedeoxynucleotides to MDR1 mRNA[J]. Patho-bidogy,2004,71(3):123-128.
[36]郭华,张庆林,王成伟,等.反义肽核酸阻断人神经母细胞瘤多药耐药相关蛋白P-糖蛋自的表达[J].中国医学科学院学报,2005,27(3):300-304.
[37] Leirdal M,Sioud M.Gene-array analysis of glioma cells after treatment with an anti-PKC alpha siRNA:a general protocol [J].Methods in Mol Biol,2004,252:493-500.
[38] Fan QW,Weiss WA.RNA interference against a glioma-derived allele of EGFR induces blockade at G2M [J].Oncogene, 2005, 24(5): 829-837.
[39] Hatano M,Mizuno M,Yoahida J.Enhancement of C2-ceramide antitumor activity by small interfering RNA on X chromosome linked inhibitor of apoptosis protein in resistant human glioma cells[J].J Neurosurg,2004,101(1):119-127.
[40] Gondi CS,Lakka SS,Dinh DH,et al.RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas [J]. Oncogene, 2004, 23(52): 8486-8496.
[41]杨翔云,赖小刚,张勇,等.干扰CIC2基因表达对胶质瘤BT-325细胞生长的影响[J].中国康复理论与实践,2006,12 (5): 378-380.
[42]杨翔云,赖小刚.张勇,等.siRNA干扰CIC-2表达对人胶质瘤U87细胞增殖的抑作用[J].癌症,2006,25(7): 805-810.
[43]赵澎.胡微,张亚卓,等.RNA干扰技术逆转神经胶质瘤细胞多药耐药性[J].中华肿瘤杂志,2006,28(3):183-187.
[44]孙卫东,于如同,马衍刚.短发夹RNA沉默hTERT基因抑制裸鼠皮下人脑胶质瘤生长的实验研究[J].徐州医学院学报,2007,27(5):290-294.